ReviewBMC ophthalmology2026
Fellow-eye effect of intravitreal aflibercept 8mg in a patient with bilateral refractory nAMD: a case report and literature review.
Review in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The fellow eye effect.Eye (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIntravitreal anti–vascular endothelial growth factor (anti-VEGF) therapy remains first-line therapy for the treatment of neovascular age-related macular degeneration (nAMD), but the high frequency of injections imposes a substantial burden on elderly patients. High-dose aflibercept 8 mg has been shown to extend dosing intervals while maintaining anatomical control. Fellow-eye effects have been reported with other anti-VEGF agents but not with aflibercept 8 mg. CASE PRESENTATION: An 89-year-old woman with bilateral refractory nAMD had received 23 prior anti-VEGF injections in the right eye. Owing to financial constraints, she underwent unilateral aflibercept 8 mg injection in the right eye only. Baseline best-corrected visual acuity (BCVA) was 0.82 the logarithm of the minimum angle of resolution (logMAR) in the right eye and 1.0 logMAR in the left eye. One week after intravitreal injection, optical coherence tomography (OCT) showed marked bilateral improvement: central subfield thickness (CST) decreased from 629 to 327 μm in the treated eye and from 357 to 308 μm in the untreated fellow eye. BCVA remained stable in the treated eye, while improved to 0.70 logMAR in the fellow eye.
conclusionThis is the first reported case of a fellow-eye effect associated with aflibercept 8 mg. The findings suggest a potential systemic effect of high-dose aflibercept, but it should be noted that, for patients with bilateral nAMD, bilateral treatment is still necessary to avoid insufficient treatment of the contralateral eye.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.